Observations on the Laron syndrome originally offered the opportunity to explore the effect of insulin-like growth factor 1 (IGF-1) deficiency on human hair growth and differentiation. According to its expression in the dermal hair papilla, IGF-1 is likely involved in reciprocal signaling. It has been shown to affect follicular proliferation, tissue remodeling, and the hair growth cycle, as well as follicular differentiation, identifying IGF-1 signaling as an important mitogenic and morphogenetic regulator in hair follicle biology. Of all the cytokines or growth factors that have been postulated to play a role in hair follicles, ultimately IGF-1 is known to be regulated by androgens. Accordingly, dermal papillary cells from balding scalp follicles were found to secrete significantly less IGF-1 than their counterparts from nonbalding scalp follicles. Herein, hypotrichosis in primary growth hormone deficiency, and a lack of response of female and male androgenetic-type alopecia to treatment with topical minoxidil and oral finasteride in patients who had undergone surgical resection of the pituitary gland, provide further evidence for an effect of IGF-1 on hair growth and alopecia.

Keywords:
IGF-1, Growth hormone deficiency, Laron syndrome, Hypophysectomy, Hypotrichosis, Androgenetic alopecia
1.
Laron Z, Pertzelan A, Mannheimer S: Genetic pituitary dwarfism with high serum concentration of growth hormone - a new inborn error of metabolism? Isr J Med Sci 1966;2:152-155.
2.
Laron Z: Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab 2004;89:1031-1044.
3.
Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Fiedler PJ: The little women of Loja - growth hormone-receptor deficiency in an inbred population of southern Ecuador. N Engl J Med 1990;323:1367-1374.
4.
Guevara-Aguirre J, Rosenbloom AL, Vaccarello MA, Fielder PJ, de la Vega A, Diamond FB Jr, Rosenfeld RG: Growth hormone receptor deficiency (Laron syndrome): clinical and genetic characteristics. Acta Paediat Scand Suppl 1991;377:96-103.
5.
Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Francke U: Growth hormone receptor deficiency in Ecuador. J Clin Endocrinol Metab 1999;84:4436-4443.
6.
Laron Z, Anin S, Klipper-Aurbach Y, Klinger B: Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet 1992;339:1258-1261.
7.
Lurie R, Ben-Amitai D, Laron Z: Laron syndrome (primary growth hormone insensitivity): a unique model to explore the effect of insulin-like growth factor 1 deficiency on human hair. Dermatology 2004;208:314-318.
8.
Paus R, Cotsarelis G: The biology of hair follicles. N Engl J Med 1999;341:491-497.
9.
Paus R, Müller-Röver S, Botchkarev VA: Chronobiology of the hair follicle: hunting the “hair cycle clock.” J Invest Dermatol Symp Proc 1999;4:338-345.
10.
Stenn KS, Combates NJ, Eilertsen KH, Gordon JS, Pardinas JR, Parimoo S, Prouty SM: Hair follicle growth controls. Dermatol Clin 1996;14:543-558.
11.
Weger N, Schlake T: IGF-I signalling controls the hair growth cycle and the differentiation of hair shafts. J Invest Dermatol 2005;125:873-882.
12.
Trüeb RM, Spycher MA, Schumacher F, Burg G: Pili torti et canaliculi in ectodermal dysplasia (in German). Hautarzt 1994;45:372-377.
13.
Ben Amitai D, Lurie R, Laron Z: I-GF-1 signalling controls the hair growth cycle and the differentiation of hair shafts. J Invest Dermatol 2006;126:2135; author reply 2135-2136.
14.
Yamada S, Fukuhara N, Nishioka H, Yamaguchi-Okada M, Takeshita A, Takeuchi Y: Scalp hair loss after transsphenoidal adenomectomy in patients with acromegaly. Clin Endocrinol (Oxf) 2013;79:386-393.
15.
Nakauchi Y, Kumon Y, Yamasaki H, Tahara K, Kurisaka M, Hashimoto K: Scalp hair loss caused by octreotide in a patient with acromegaly: a case report. Endocr J 1995;42:385-389.
16.
Alvarez-Escola C, Cárdenas-Salas JJ, Pelegrina B, Sanz-Valtierra A, Lecumberri B: Severe scalp hair loss in a female patient with acromegaly treated with lanreotide autogel after unsuccessful surgery. Clin Case Rep 2015;3:945-948.
17.
Olszewska M, Warszawik O, Rakowska A, Słowińska M, Rudnicka L: Methods of hair loss evaluation in patients with endocrine disorders. Endokrynol Pol 2010;61:406-411.
18.
Trüeb RM: Hormones and hair growth (in German). Hautarzt 2010;61:487-495.
19.
Trüeb RM: Pharmacologic interventions in aging hair. Clin Interv Aging 2006;1:121-129.
20.
Chein E: Age Reversal, from Hormones to Telomeres. Salt Lake City, WorldLink Medical Publishing, 1998.
21.
Japsen B: AMA report questions science behind using hormones as anti-aging treatment. The Chicago Tribune, June 15, 2009 (retrieved July 17, 2009).
22.
Sattler FR: Growth hormone in the aging male. Best Pract Res Clin Endocrinol Metab 2013;27:541-555.
23.
Bartke A, Brown-Borg H: Life extension in the dwarf mouse. Curr Top Dev Biol 2004;63:189-225.
24.
Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S, de Cabo R, Cohen P, Longo VD: Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 2011;3:70ra13.
25.
Panchaprateep R, Asawanonda P: Insulin-like growth factor-1: roles in androgenetic alopecia. Exp Dermatol 2014;23:216-218.
26.
Noordam R, Gunn DA, van Drielen K, Westgate G, Slagboom P, de Craen AJ, van Heemst D: Both low circulating insulin-like growth factor-1 and high-density lipoprotein cholesterol are associated with hair loss in middle-aged women. Br J Dermatol 2016;175:728-734.
27.
Giordano S, Romeo M, Lankinen P: Platelet-rich plasma for androgenetic alopecia: does it work? Evidence from meta analysis. J Cosmet Dermatol 2017, Epub ahead of print.
28.
Ayatollahi A, Hosseini H, Gholami J, Mirminachi B, Firooz F, Firooz A: Platelet rich plasma for treatment of non-scarring hair loss: systematic review of literature. J Dermatolog Treat 2017, Epub ahead of print.
29.
Castro RF, Azzalis LA, Feder D, Perazzo FF, Pereira EC, Junqueira VB, Rocha KC, Machado CD, Paschoal FC, Gnann LA, Fonseca FL: Safety and efficacy analysis of liposomal insulin-like growth factor-1 in a fluid gel formulation for hair-loss treatment in a hamster model. Clin Exp Dermatol 2012;37:909-912.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.